ABNL-MARRO
The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 105 patients (estimated)
- Sponsors
- Vanderbilt-Ingram Cancer Center
- Collaborators
- Incyte Corporation, Theradex, Taiho Oncology, Inc.
- Tags
- Chemotherapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1799
- NCT Identifier
- NCT04061421
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.